$DARE

Dare Bioscience, Inc.

Daré Bioscience is a health biotechnology company focused on developing and commercializing products for women’s health. Its portfolio spans contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Daré pursues FDA approval, Section 503B compounding and non-prescription consumer products as pathways to market, and earns money through commercial product sales and licensing arrangements. Its products include DARE to PLAY, a compounded sildenafil cream; the planned DARE to RESTORE line of vaginal probiotic suppositories, beginning with Flora Sync LF5; and investigational candidates including Ovaprene, a hormone-free monthly contraceptive. XACIATO, an FDA-approved vaginal gel for bacterial vaginosis, is licensed to Organon for commercialization. Daré also has DARE-HRT1, an intravaginal hormone therapy candidate. The company is headquartered in San Diego, California.

1
1
2

No SEC Form 4 filings for $DARE in the last 30 days.

See all $DARE insider activity →

Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington

DARE Q3'26 Earnings: EPS estimate is (0.13) USD

Dare Bioscience (DARE) will report Q3'26 earnings on November 16. Analysts expect $2.04M revenue and a loss of $0.13 per share. Results will be released after market close.

DARE sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning DARE (Dare Bioscience, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 2 bearish.

Recent DARE coverage spans earnings, corporate actions and technology.

What's driving DARE

  • Earnings miss plus extreme year-over-year revenue swing likely drives near-term downside risk and raises questions about underlying operating trajectory.

    seekingalpha.com · Nov 16, 2026

  • Near-term catalyst is operational readiness for prescription dispensing, which could improve near-term demand visibility and revenue ramp expectations.

    SEC EDGAR 8-K · Nov 16, 2026

  • Negative earnings estimate may pressure the stock ahead of the actual release.

    tradingview.com · Nov 13, 2026

  • The vote results are routine corporate governance information with no material change to capital structure or operations.

    SEC EDGAR 8-K · Nov 12, 2026

  • The new grant funding supports continued preclinical work and may reduce dilution concerns, modestly improving sentiment.

    stocktitan.net · Oct 30, 2026

AlphAI scores every news story that mentions DARE with an AI model for sentiment and relevance, and aggregates insider trades from Dare Bioscience, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DARE

Score
$DAREMedEarnings

Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington

$DARELowShareholder vote

Dare Bioscience, Inc. (DARE): Submission of Matters to a Vote of Security Holders

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. A special meeting of stockholders (the “Meeting”) of Daré Bioscience, Inc. (“Daré,” “we,” “us,” or “our”) was held on November 10, 2026 and the following proposals were voted upon by our stockholders. The proposals ar

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.

$DAREMedAI 8/10

Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.

Related tickers